The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
Elfrida R. Benjamin(Amicus Therapeutics (United States)), Maria Cecilia Della Valle(Amicus Therapeutics (United States)), Xiaoyang Wu(Amicus Therapeutics (United States)), Evan Katz(Amicus Therapeutics (United States)), Farhana Pruthi(Amicus Therapeutics (United States)), Sarah Bond(Boston Biomedical (United States)), Benjamin Bronfin(Boston Biomedical (United States)), Hadis Williams(Amicus Therapeutics (United States)), Julie Yu(Amicus Therapeutics (United States)), Daniel G. Bichet(Hôpital du Sacré-Cœur de Montréal), Dominique P. Germain(Université de Versailles Saint-Quentin-en-Yvelines), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Derralynn Hughes(The Royal Free Hospital), Raphael Schiffmann, William R. Wilcox(Emory University), Robert J. Desnick(Icahn School of Medicine at Mount Sinai), John Kirk(Amicus Therapeutics (United States)), Jay Barth(Amicus Therapeutics (United States)), Carrolee Barlow(Amicus Therapeutics (United States)), Kenneth J. Valenzano(Amicus Therapeutics (United States)), Jeff Castelli(Amicus Therapeutics (United States)), David J. Lockhart(Amicus Therapeutics (United States))
Cited by 209Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis